jeudi 12 avril 2018

Onco Actu du 12 avril 2018

1. Biologie

Researchers Use WGS, RNA-Seq to Characterize Colorectal Cancer Mutational Landscape [Genome Web]

1.1 Biologie - Gènes

Cancer Genetic Mutations not all Treatable: System to Rank Relevance of Mutations Needed [ESMO]

3.1.1 Prévention - Tabac - e-cigs

“A toxicological experiment”: Additional study needed on e-cigarette use [Stanford Medicine]

4. Dépistage, diagnostic et pronostic

NCI study revises molecular classification for most common type of lymphoma [NCI]

5. Traitements

RB1 gene mutations underlie clinical resistance to CDK 4/6 inhibitor therapy for breast cancer [Mass. General Hospital]

5.1 Traitements - Pré-clinique

Perioperative NSAIDs may prevent early metastatic relapse in post-surgical breast cancer patients [MIT News]

Cancer surgery can awaken tumor cells, but in mice a cheap pill stops metastasis [STAT]

5.12 Immunothérapies

The “Immuno Revolution”: Turning Up the Heat on Resistant Tumors [Penn Medicine]

5.12.2 Immunothérapies - CAR-T

Cellectis raises $164M for CAR-T and gene-editing programs [FierceBiotech]

5.12.3 Immunothérapies-combinaisons

With New Data, Drug Combos, Lung Cancer Experts Scramble to Keep Pace [Xconomy]

5.12.4 Immunothérapies - Essais

Roche hits pause on Tecentriq-Cotellic trial enrollment after deaths raise red flags [FiercePharma]

Roche halts enrollment in a PhII combo study of Tecentriq and Cotellic in wake of several patient deaths [EndPoints]

5.12.7 Immunothérapies - vaccins

Personalised vaccine for ovarian cancer nearly doubles two year survival rate, pilot study shows [The Telegraph]

5.2.1 Pharma - Partenariats

Molecular Partners gets AZ support for lung cancer trial [FierceBiotech]

5.3 Traitements - FDA, EMA, NICE...

Demand cancer drugs that truly help patients [Nature]

5.6.4 ESMO - Poumon

Alectinib Provides Longer Symptom Improvement than Crizotinib in ALK-positive Lung Cancer [ESMO]

Further Evidence that Immunotherapy Provides a Long-term Survival Benefit for Lung Cancer Patients [ESMO]

5.9.8 AACR - Pharma

Cellectis to Present Data at the 2018 AACR Annual Meeting [Cellectis]

6.1 Observation

Cancer Risk Rises as Patients Wait for Diagnostic Testing [Penn Medicine]

6.5 Médecines alternatives

The dubious cancer “virotherapy” Rigvir returns with an equally dubious case report [Respectful Insolence]

6.6 Publications

French Scientists Petition for Firm Stance Against Springer [The Scientist]

6.9 Controverses

J&J, Imerys unit must pay $117 million in N.J. asbestos cancer case [Reuters]